Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Which Brilliant Home Gadget Can't You Reside Without? - 25 Movies That Leaving an Imprint with Inventive Innovation
- 3Find the Specialty of Calligraphy: Dominating the Exquisite Art of Penmanship
- 4Ancient Pompeii construction site reveals the process for creating Roman concrete
- 5Vote In favor of Your Favored Shades
- Fireballs and a full moon. Here’s how to see two celestial events this week
- International issues on the agenda as Frances's Macron visits China
- Moon rocket and weather are on NASA's side for the first astronaut launch in decades
- What's Your Number one Superhuman Film Made?
- Dental Embed Developments: Upsetting Current Dentistry
- Jamie Dimon warns Iran war could drive inflation, interest rates higher
- Arctic sea ice hits lowest winter level as heat records are shattered worldwide
- Aurora chaser catches a fox basking in the glow of Finland's legendary 'fox fires' (photos)
- Ways to track down the Right Criminal Legal counselor
